Sam Lee - 09 Jan 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Role
President and Co-CEO
Signature
/s/ Sam Lee
Issuer symbol
COCP
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
13 Jan 2026, 16:10:09 UTC
Previous filing
11 Oct 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Sam President and Co-CEO 19805 N. CREEK PARKWAY, BOTHELL /s/ Sam Lee 13 Jan 2026 0001602074

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COCP Stock Options (Right to Buy) Award $0 +49,229 $0.000000 49,229 09 Jan 2026 Common Stock 49,229 $1.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date.